Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15829060 | 0.88 | PIK3CD (0.35) | PIK3CD | |
| SCHEMBL15033923 | 0.82 | — | — | |
| SCHEMBL15829058 | 0.81 | DPP4 (0.33) | PIK3CD | |
| SCHEMBL15033766 | 0.78 | DPP4 (0.31) | — | |
| SCHEMBL15396098 | 0.76 | ACE (0.33) | — | |
| SCHEMBL21343611 | 0.73 | PIK3CD (0.43) | PIK3CD | |
| SCHEMBL15033762 | 0.73 | PIK3CD (0.43) | PIK3CD | |
| SCHEMBL15829079 | 0.72 | PIK3CD (0.31) | PIK3CD | |
| SCHEMBL15396009 | 0.71 | — | — | |
| SCHEMBL15829061 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369502-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20160362416-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160083395-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-9233974-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150361087-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-17 | — | — | US | disclosed |
| US-8940718-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2014-06-26 | — | — | US | disclosed |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369502-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885 |
| US-20160362416-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885 |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885 |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885 |
| US-20150361087-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885 |
| US-20160083395-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.